Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha Pipeline Review Analysis Report 2019

Posted on 2019-10-01 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, US, 2019-Oct-01 — /EPR Network/ —Market Research Hub (MRH) has actively uploaded a smart research report titled “Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha-Pipeline Review, H2 2019”, to its broad online database. The primary motive of this study is to impart vital details associated to development of the Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha. The assessment includes brief knowledge about market size, Y-o-Y growth, market dynamics and competitive scenario expected to transform in the near future. Ever section of the report contains imperative market data that can prove useful for new entrants and industry players to draw crucial tactics.

Get Sample Copy at https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519487

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha – Pipeline Review, H2 2019

Summary

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) – Granulocyte macrophage colony stimulating factor receptor subunit alpha also known as CD116 is a receptor for granulocyte macrophage colony-stimulating factor. It is a member of the cytokine family of receptors. It plays an important role in controls the production, differentiation, and function of granulocytes and macrophages.

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 4 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Respiratory, Infectious Disease, Toxicology, Dermatology, Gastrointestinal and Hematological Disorders which include indications Melanoma, Alzheimer’s Disease, Lung Disease, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Respiratory Distress Syndrome, Appendicitis, Chemotherapy Effects, Chemotherapy Induced Neutropenia, Crohn’s Disease (Regional Enteritis), Epithelial Ovarian Cancer, Lung Infections, Lung Injury, Malignant Pleural Mesothelioma, Metastatic Colorectal Cancer, Mild Cognitive Impairment, Mycobacterium Infections, Neurology, Peritoneal Cancer, Peritonitis, Radiation Injury, Respiratory Syncytial Virus (RSV) Infections, Skin Ulcers and Wounds.

The latest report Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha – Pipeline Review, H2 2019, outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

– The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
– The report reviews Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics and enlists all their major and minor projects
– The report assesses Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics

Browse Complete Report at https://www.marketresearchhub.com/report/granulocyte-macrophage-colony-stimulating-factor-receptor-subunit-alpha-pipeline-review-h2-2019-report.html

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) – Overview
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) – Companies Involved in Therapeutics Development
Aduro BioTech Inc
Bolder Biotechnology Inc
Celdara Medical LLC
Profarma
Savara Inc
Targovax ASA
XL-protein GmbH
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) – Drug Profiles
BBT-007 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMJG-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GVAX Vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONCOS-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for RSV Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sargramostim – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sargramostim – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Melanoma – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-150 – Drug Profile
Product Description
Mechanism Of Action

Continued………#@

Make An Enquiry About This Report https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2519487

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceuticals market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick